January 20, 2014
Astellas Pharma announced on January 17 that it received approval on the same day for its selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor Suglat 25 mg/50 mg Tablets (ipragliflozin L-proline) for the treatment of type 2 diabetes in Japan. This is the...read more